Obesity and arterial compliance alterations

Current Vascular Pharmacology

Volumn 8, Issue 2, 2010, Pages 155-168

  Seifalian, Alexander M ^a,b   Filippatos, Theodosios D ^c   Joshi, Jatin ^a   Mikhailidis, Dimitri P ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiotensin; Artery; Compliance; Elasticity; Insulin; Leptin; Metabolic syndrome; Nitric oxide; Obesity; Stiffness

Indexed keywords

ANGIOTENSIN II; C PEPTIDE; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; GLUCOSE; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADIPOSE TISSUE; ALBUMINURIA; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTERY DIAMETER; AUGMENTATION INDEX; BLOOD PRESSURE; BODY FAT DISTRIBUTION; CALCIUM CELL LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOTHELIUM; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; MENOPAUSE; OBESITY; PREGNANCY DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING; SMOOTH MUSCLE FIBER; WEIGHT GAIN; WEIGHT REDUCTION;

ABDOMINAL FAT; ANIMALS; ARTERIES; CARDIOVASCULAR DISEASES; COMPLIANCE; ELASTICITY; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 77949529018     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110790886956     Document Type: Review

References (211)

1. Balkau B, Deanfield JE, Despres JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116: 1942-51.
2. Swallen KC, Reither EN, Haas SA, Meier AM. Overweight, obesity, and health-related quality of life among adolescents: the National Longitudinal Study of Adolescent Health. Pediatrics 2005; 115: 340-7.
3. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-9.
4. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
5. Hauner H, Bognar E, Blum A. Body fat distribution and its association with metabolic and hormonal risk factors in women with angiographically assessed coronary artery disease. Evidence for the presence of a metabolic syndrome. Atherosclerosis 1994; 105: 209-16.
6. Larsson B, Bengtsson C, Bjorntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol 1992; 135: 266-73.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283-96.
9. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
10. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 932-43.
11. Wykretowicz A, Adamska K, Guzik P, Krauze T, Wysocki H. Indices of vascular stiffness and wave reflection in relation to body mass index or body fat in healthy subjects. Clin Exp Pharmacol Physiol 2007; 34: 1005-9.
12. Czernichow S, Bertrais S, Oppert JM, et al. Body composition and fat repartition in relation to structure and function of large arteries in middle-aged adults (the SU.VI.MAX study). Int J Obes (Lond) 2005; 29: 826-32.
13. Sutton-Tyrrell K, Newman A, Simonsick EM, et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001; 38: 429-33.
14. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension 2003; 42: 468-73.
15. Resnick LM, Militianu D, Cunnings AJ, Pipe JG, Evelhoch JL, Soulen RL. Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Hypertension 1997; 30: 654-9.
16. Nemes A, Gavaller H, Csajbok E, Forster T, Csanady M. Obesity is associated with aortic enlargement and increased stiffness: an echocardiographic study. Int J Cardiovasc Imaging 2008; 24: 165-71.
17. Mitchell GF, Guo CY, Benjamin EJ, et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation 2007; 115: 2628-36.
18. Toto-Moukouo JJ, Achimastos A, Asmar RG, Hugues CJ, Safar ME. Pulse wave velocity in patients with obesity and hypertension. Am Heart J 1986; 112: 136-40.
19. van Popele NM, Westendorp IC, Bots ML, et al. Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women. Diabetologia 2000; 43: 665-72.
20. Zebekakis PE, Nawrot T, Thijs L, et al. Obesity is associated with increased arterial stiffness from adolescence until old age. J Hypertens 2005; 23: 1839-46.
21. Danias PG, Tritos NA, Stuber M, Botnar RM, Kissinger KV, Manning WJ. Comparison of aortic elasticity determined by cardiovascular magnetic resonance imaging in obese vs. lean adults. Am J Cardiol 2003; 91: 195-9.
22. Orr JS, Gentile CL, Davy BM, Davy KP. Large artery stiffening with weight gain in humans: role of visceral fat accumulation. Hypertension 2008; 51: 1519-24.
23. Moon JY, Park S, Ahn CM, et al. Increase of metabolic syndrome score is an independent determinant of increasing pulse pressure. Yonsei Med J 2008; 49: 63-70.
24. Kovaite M, Petrulioniene Z, Ryliskyte L, et al. Systemic assessment of arterial wall structure and function in metabolic syndrome. Proc West Pharmacol Soc 2007; 50: 123-30.
25. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006; 58 (Suppl): 81-8.
26. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004; 44: 112-6.
27. Boutouyrie P, Bezie Y, Lacolley P, et al. In vivo/in vitro comparison of rat abdominal aorta wall viscosity. Influence of endothelial function. Arterioscler Thromb Vasc Biol 1997; 17: 1346-55.
28. Levy BI, Benessiano J, Poitevin P, Safar ME. Endothelium-dependent mechanical properties of the carotid artery in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens Suppl 1989; 7: S118-9.
29. Singhal A. Endothelial dysfunction: role in obesity-related disorders and the early origins of CVD. Proc Nutr Soc 2005; 64: 15-22.
30. Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002; 26: 754-64.
31. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
32. Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999; 23: 936-42.
33. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 1999; 48: 821-7.
34. Wang Y, Marsden PA. Nitric oxide synthases: gene structure and regulation. Adv Pharmacol 1995; 34: 71-90.
35. Nishida K, Harrison DG, Navas JP, et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90: 2092-6.
36. Awolesi MA, Sessa WC, Sumpio BE. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. J Clin Invest 1995; 96: 1449-54.
37. Zembowicz A, Tang JL, Wu KK. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem 1995; 270: 17006-10.
38. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995; 76: 958-62.
39. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-45.
40. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342: 454-60.
41. Yoshizumi M, Perrella MA, Burnett JC, Jr., Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-9.
42. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007; 293: H1115-21.
43. Valerio A, Cardile A, Cozzi V, et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006; 116: 2791-8.
44. Mohan S, Reddick RL, Musi N, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008; 88: 515-28.
45. Elizalde M, Ryden M, van Harmelen V, et al. Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res 2000; 41: 1244-51.
46. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005; 25: 989-94.
47. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230-9.
48. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96: 3266-8.
49. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 1995; 26: 764-70.
50. Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 1983; 32: 217-21.
51. Mikhailidis DP, Mikhailidis AM, Barradas MA, Dandona P. Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism 1983; 32: 717-21.
52. Barradas MA, Mikhailidis DP, Dandona P. The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract 1987; 3: 9-19.
53. Huber LR, Hogue CJ, Stein AD, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. Am J Obstet Gynecol 2006; 194: 1290-5.
54. Virmani R, Avolio AP, Mergner WJ, et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol 1991; 139: 1119-29.
55. Risler N, Castro C, Cruzado M, Gonzalez S, Miatello R. Proteoglycans production by aortic vascular smooth muscle cells from hypertensive rats. Biocell 2003; 27: 189-96.
56. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312-8.
57. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100: 2267-75.
58. Rizzoni D, Porteri E, Piccoli A, et al. Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 1998; 32: 305-10.
59. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-24.
60. Fukuda N, Hu WY, Satoh C, et al. Contribution of synthetic phenotype on the enhanced angiotensin II-generating system in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 1999; 17: 1099-107.
61. Emoto N, Onose H, Yamada H, Minami S, Tsushima T, Wakabayashi I. Growth factors increase pericellular proteoglycans independently of their mitogenic effects on A10 rat vascular smooth muscle cells. Int J Biochem Cell Biol 1998; 30: 47-54.
62. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-9.
63. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-40.
64. Belmadani S, Zerfaoui M, Boulares HA, Palen DI, Matrougui K. Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol 2008; 295: H69-76.
65. Hixon ML, Gualberto A. Vascular smooth muscle polyploidization-from mitotic checkpoints to hypertension. Cell Cycle 2003; 2: 105-10.
66. Levy BI, Schiffrin EL, Mourad JJ, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008; 118: 968-76.
67. Eikelis N, Esler M. The neurobiology of human obesity. Exp Physiol 2005; 90: 673-82.
68. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
69. Farin HM, Abbasi F, Reaven GM. Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults. Am J Clin Nutr 2006; 83: 47-51.
70. Avogaro A. Insulin resistance: trigger or concomitant factor in the metabolic syndrome. Panminerva Med 2006; 48: 3-12.
71. Westerbacka J, Yki-Jarvinen H. Arterial stiffness and insulin resistance. Semin Vasc Med 2002; 2: 157-64.
72. Yki-Jarvinen H, Westerbacka J. Vascular actions of insulin in obesity. Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): S25-8.
73. Westerbacka J, Seppala-Lindroos A, Yki-Jarvinen H. Resistance to acute insulin induced decreases in large artery stiffness accompanies the insulin resistance syndrome. J Clin Endocrinol Metab 2001; 86: 5262-8.
74. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-5.
75. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998; 41: 369-79.
76. Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med 2004; 199: 347-56.
77. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404.
78. Airaksinen KE, Salmela PI, Linnaluoto MK, Ikaheimo MJ, Ahola K, Ryhanen LJ. Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 1993; 27: 942-5.
79. Zemel MB. The role of dairy foods in weight management. J Am Coll Nutr 2005; 24: 537S-546S.
80. Zemel MB, Richards J, Milstead A, Campbell P. Effects of calcium and dairy on body composition and weight loss in African-American adults. Obes Res 2005; 13: 1218-25.
81. Sun X, Zemel MB. Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine expression. Obesity (Silver Spring) 2007; 15: 340-8.
82. Takahashi E, Ito M, Miyamoto N, Nagasu T, Ino M, Tanaka I. Increased glucose tolerance in N-type Ca2+ channel alpha(1B)-subunit gene-deficient mice. Int J Mol Med 2005; 15: 937-44.
83. Zemel MB. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol Cell Biochem 1998; 188: 129-36.
84. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-108.
85. Yaginuma T, Avolio A, O'Rourke M, et al. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Cardiovasc Res 1986; 20: 153-60.
86. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 91: 1432-43.
87. Giannattasio C, Failla M, Calchera I, et al. Pharmacological improvement of large arteries properties. Pathol Biol (Paris) 1999; 47: 744-51.
88. Wilkinson I, Cockcroft JR. Cholesterol, lipids and arterial stiffness. Adv Cardiol 2007; 44: 261-77.
89. Wilkinson IB, Prasad K, Hall IR, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol 2002; 39: 1005-11.
90. Dart AM, Lacombe F, Yeoh JK, et al. Aortic distensibility in patients with isolated hypercholesterolaemia, coronary artery disease, or cardiac transplant. Lancet 1991; 338: 270-3.
91. Lehmann ED, Watts GF, Fatemi-Langroudi B, Gosling RG. Aortic compliance in young patients with heterozygous familial hypercholesterolaemia. Clin Sci (Lond) 1992; 83: 717-21.
92. Giannattasio C, Mangoni AA, Failla M, et al. Combined effects of hypertension and hypercholesterolemia on radial artery function. Hypertension 1997; 29: 583-6.
93. Toikka JO, Niemi P, Ahotupa M, et al. Large-artery elastic properties in young men : relationships to serum lipoproteins and oxidized low-density lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19: 436-41.
94. Lehmann ED, Watts GF, Gosling RG. Aortic distensibility and hypercholesterolaemia. Lancet 1992; 340: 1171-2.
95. Kupari M, Hekali P, Keto P, Poutanen VP, Tikkanen MJ, Standerstkjold-Nordenstam CG. Relation of aortic stiffness to factors modifying the risk of atherosclerosis in healthy people. Arterioscler Thromb 1994; 14: 386-94.
96. Saba PS, Roman MJ, Longhini C, et al. Carotid intimal-medial thickness and stiffness are not affected by hypercholesterolemia in uncomplicated essential hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2788-94.
97. Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007; 5: 227-37.
98. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17: 1513-7.
99. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
100. Hanon O, Girerd X, Luong V, Jeunemaitre X, Laurent S, Safar ME. Association between the apolipoprotein E polymorphism and arterial wall thickness in asymptomatic adults. J Hypertens 2000; 18: 431-6.
101. Cameron JD, Jennings GL, Dart AM. The relationship between arterial compliance, age, blood pressure and serum lipid levels. J Hypertens 1995; 13: 1718-23.
102. Byfield FJ, Tikku S, Rothblat GH, Gooch KJ, Levitan I. OxLDL increases endothelial stiffness, force generation, and network formation. J Lipid Res 2006; 47: 715-23.
103. Kampus P, Kals J, Ristimae T, et al. Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein. J Hypertens 2007; 25: 819-25.
104. Erdmann J, Kallabis B, Oppel U, Sypchenko O, Wagenpfeil S, Schusdziarra V. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain. Am J Physiol Endocrinol Metab 2008; 294(3): E568-75.
105. Johansson BL, Kernell A, Sjoberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993; 77: 976-81.
106. Rebsomen L, Khammar A, Raccah D, Tsimaratos M. C-Peptide effects on renal physiology and diabetes. Exp Diabetes Res 2008; 2008: 281536.
107. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17: 181-9.
108. Johansson BL, Sjoberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35: 121-8.
109. Johansson BL, Sundell J, Ekberg K, et al. C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab 2004; 286: E14-9.
110. Hansen A, Johansson BL, Wahren J, von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002; 51: 3077-82.
111. Wahren J, Ekberg K, Johansson J, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000; 278: E759-68.
112. Sundell J, Laine H, Nuutila P, et al. The effects of insulin and short-term hyperglycaemia on myocardial blood flow in young men with uncomplicated Type I diabetes. Diabetologia 2002; 45: 775-82.
113. Wu ZH, Zhao SP. Adipocyte: a potential target for the treatment of atherosclerosis. Med Hypotheses 2006; 67: 82-6.
114. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol 2007; 2: 31-56.
115. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30: 323-6.
116. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-2.
117. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Berenson GS. Racial (black-white) divergence in the association between adiponectin and arterial stiffness in asymptomatic young adults: the Bogalusa heart study. Am J Hypertens 2008; 21: 553-7.
118. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006; 7: 761-71.
119. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and biology. Vitam Horm 2005; 71: 345-72.
120. Wauters M, Considine R, Lofgren A, et al. Associations of leptin with body fat distribution and metabolic parameters in non-insulin-dependent diabetic patients: no effect of apolipoprotein E polymorphism. Metabolism 2000; 49: 724-30.
121. Stylianou C, Galli-Tsinopoulou A, Farmakiotis D, et al. Ghrelin and leptin levels in obese adolescents. Relationship with body fat and insulin resistance. Hormones (Athens) 2007; 6: 295-303.
122. Kettaneh A, Heude B, Romon M, et al. High plasma leptin predicts an increase in subcutaneous adiposity in children and adults. Eur J Clin Nutr 2007; 61: 719-26.
123. Bednarek-Tupikowska G, Filus A, Kuliczkowska-Plaksej J, Tupikowski K, Bohdanowicz-Pawlak A, Milewicz A. Serum leptin concentrations in pre- and postmenopausal women on sex hormone therapy. Gynecol Endocrinol 2006; 22: 207-12.
124. Carraro R, Ruiz-Torres A. Relationship of serum leptin concentration with age, gender, and biomedical parameters in healthy, nonobese subjects. Arch Gerontol Geriatr 2006; 43: 301-12.
125. Zhang Y, Scarpace PJ. The role of leptin in leptin resistance and obesity. Physiol Behav 2006; 88: 249-56.
126. Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res 2004; 59: 225-44.
127. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243-52.
128. Rahmouni K, Haynes WG. Endothelial effects of leptin: implications in health and diseases. Curr Diab Rep 2005; 5: 260-6.
129. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 24: 789-801.
130. Correia ML, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006; 8: 603-10.
131. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005; 54: 2012-8.
132. Schafer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004; 24: 112-7.
133. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106: 1919-24.
134. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-9.
135. Corsonello A, Perticone F, Malara A, et al. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord 2003; 27: 566-73.
136. De Mitrio V, De Pergola G, Vettor R, et al. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism 1999; 48: 960-4.
137. Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. Ann N Y Acad Sci 2001; 947: 134-41.
138. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
139. Elbatarny HS, Maurice DH. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am J Physiol Endocrinol Metab 2005; 289: E695-702.
140. Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 2002; 16: 1057-63.
141. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens A 1991; 13: 277-96.
142. Verlohren S, Dubrovska G, Tsang SY, et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004; 44: 271-6.
143. Gollasch M, Dubrovska G. Paracrine role for periadventitial adipose tissue in the regulation of arterial tone. Trends Pharmacol Sci 2004; 25: 647-53.
144. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Reninangiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26: 831-43.
145. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-8.
146. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98: 2453-60.
147. Jesmin S, Sakuma I, Hattori Y, Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol 2003; 23: 2021-6.
148. Rizzoni D, Porteri E, Guelfi D, et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001; 103: 1238-44.
149. Benetos A, Safar ME. Aortic collagen, aortic stiffness, and AT1 receptors in experimental and human hypertension. Can J Physiol Pharmacol 1996; 74: 862-6.
150. Kato H, Suzuki H, Tajima S, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9: 17-22.
151. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37: 1444-9.
152. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 1617-23.
153. Diamant M, Lamb HJ, van de Ree MA, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 1495-501.
154. Srinivasan SR, Bao W, Wattigney WA, Berenson GS. Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: the Bogalusa Heart Study. Metabolism 1996; 45: 235-240.
155. Juonala M, Jarvisalo MJ, Maki-Torkko N, Kahonen M, Viikari JS, Raitakari OT. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation 2005; 112: 1486-93.
156. Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 358: 1400-4.
157. Iannuzzi A, Licenziati MR, Acampora C, et al. Increased carotid intima-media thickness and stiffness in obese children. Diabetes Care 2004; 27: 2506-8.
158. Iannuzzi A, Licenziati MR, Acampora C, et al. Carotid artery stiffness in obese children with the metabolic syndrome. Am J Cardiol 2006; 97: 528-31.
159. Zaydun G, Tomiyama H, Hashimoto H, et al. Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase. Atherosclerosis 2006; 184: 137-42.
160. Augoulea A, Mastorakos G, Lambrinoudaki I, Christodoulakos G, Creatsas G. Role of postmenopausal hormone replacement therapy on body fat gain and leptin levels. Gynecol Endocrinol 2005; 20: 227-35.
161. da Costa LS, de Oliveira MA, Rubim VS, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004; 94: 1453-6.
162. Miura S, Tanaka E, Mori A, et al. Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 2003; 45: 293-8.
163. Oren S, Isakov I, Golzman B, et al. The influence of smoking cessation on hemodynamics and arterial compliance. Angiology 2006; 57: 564-8.
164. Li H, Srinivasan SR, Berenson GS. Comparison of the measures of pulsatile arterial function between asymptomatic younger adult smokers and former smokers: the Bogalusa Heart Study. Am J Hypertens 2006; 19: 897-901.
165. van den Berkmortel FW, Wollersheim H, van Langen H, Smilde TJ, den Arend J, Thien T. Two years of smoking cessation does not reduce arterial wall thickness and stiffness. Neth J Med 2004; 62: 235-41.
166. Villareal DT, Miller BV, 3rd, Banks M, Fontana L, Sinacore DR, Klein S. Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am J Clin Nutr 2006; 84: 1317-23.
167. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-68.
168. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15-22.
169. Nakou E, Filippatos TD, Liberopoulos EN, et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008; 9: 1629-39.
170. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006.
171. Dengel DR, Kelly AS, Olson TP, Kaiser DR, Dengel JL, Bank AJ. Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism 2006; 55: 907-11.
172. Shargorodsky M, Fleed A, Boaz M, Gavish D, Zimlichman R. The effect of a rapid weight loss induced by laparoscopic adjustable gastric banding on arterial stiffness, metabolic and inflammatory parameters in patients with morbid obesity. Int J Obes (Lond) 2006; 30: 1632-8.
173. Randall OS, Kwagyan J, Huang Z, Xu S, Ketete M, Maqbool AR. Effect of diet and exercise on pulse pressure and cardiac function in morbid obesity: analysis of 24-hour ambulatory blood pressure. J Clin Hypertens (Greenwich) 2005; 7: 455-63.
174. Ikonomidis I, Mazarakis A, Papadopoulos C, et al. Weight loss after bariatric surgery improves aortic elastic properties and left ventricular
175. Barinas-Mitchell E, Kuller LH, Sutton-Tyrrell K, et al. Effect of weight loss and nutritional intervention on arterial stiffness in type 2 diabetes. Diabetes Care 2006; 29: 2218-22.
176. Schneider R, Golzman B, Turkot S, Kogan J, Oren S. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005; 330: 157-60.
177. Siebenhofer A, Horvath K, Jeitler K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009; (3): CD007654.
178. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007; 3: 817-21.
179. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-8.
180. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.
181. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009; 15: 490-516.
182. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
183. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002; 20: 2257-67.
184. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008; 24: 1919-29.
185. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008; 9: 3151-8.
186. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
187. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
188. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83.
189. Sekuri C, Tavli T, Avsar A, Sozcuer H, Uyanik BS, Ari Z. The acute effect of orlistat on endothelial function in young obese women. Int J Clin Pharmacol Res 2003; 23: 111-7.
190. Brook RD, Bard RL, Glazewski L, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004; 93: 1012-6.
191. Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003; 26: 1667-72.
192. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003; 5: 195-201.
193. Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162: 2428-35.
194. Sharma B, Henderson DC. Sibutramine: current status as an antiobesity drug and its future perspectives. Expert Opin Pharmacother 2008; 9: 2161-73.
195. Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008; 9(5): 420-7.
196. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 441-52.
197. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 2005; 29: 509-16.
198. Shechter M, Beigel R, Freimark D, Matetzky S, Feinberg MS. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 2006; 97: 1650-3.
199. Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007; 47: 642-52.
200. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-60.
201. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother 2008; 9: 2741-50.
202. Rajesh M, Mukhopadhyay P, Hasko G, Pacher P. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 2008; 377: 1248-52.
203. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 2007; 321: 930-7.
204. Dart AM, Kingwell BA. Pulse pressure - a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001; 37: 975-84.
205. Nakagawa N, Takahashi F, Chinda J, et al. A newly estimated glomerular filtration rate is independently associated with arterial stiffness in Japanese patients. Hypertens Res 2008; 31: 193-201.
206. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an ac tive component or an innocent bystander? Metabolism 2006; 55: 1293-301.
207. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. Intern Emerg Med 2007; 2: 19-23.
208. Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JJ. The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors. Atherosclerosis 2008; 200; 374-9.
209. Duprez DA, Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 2007; 9: 139-44.
210. Grey E, Bratteli C, Glasser SP, et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 2003; 16: 265-9.
211. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008; 199: 3-11.